Positive early pilot data for ViraxImmune provides a potential catalyst for VRAX, but the test remains in early development with no regulatory approval. Monitor for the larger 300-subject validation results expected in Q1 2027 and any partnership or regulatory developments. The $2M market cap suggests high risk; position sizing should reflect binary outcome risk.
Price Chart
Executive Summary
Virax Biolabs reported early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes, showing 88% specificity and 92% positive predictive value in a small pilot dataset. The test has been evaluated in over 120 subjects, with a larger 300-participant validation analysis expected to begin in Q4 2026 with results in Q1 2027. The company is pursuing a U.S. Laboratory Developed Test route to market, but ViraxImmune is not yet approved for diagnostic use in any jurisdiction.
Key Facts
- ViraxImmune pilot data showed 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls
- Test evaluated in more than 120 subjects in ongoing UK clinical study
- Larger validation study of 300 additional participants planned for Q4 2026 with results expected Q1 2027
- Company pursuing U.S. Laboratory Developed Test route to market
- Virax estimates up to 21 million U.S. adults may have Long COVID or related PAIS conditions, with 2.5 million new cases per year
- ViraxImmune is not approved for diagnostic use in any jurisdiction
Financial Impact
No financial figures reported; pre-revenue clinical-stage company with $2M market cap
Risk Factors
- ViraxImmune is not approved for diagnostic use and may never receive regulatory clearance
- Pilot data is preliminary and may not replicate in larger validation studies
- Company has $2M market cap with no disclosed revenue, indicating high cash burn risk and potential dilution
- Long COVID diagnostic market is competitive with multiple players developing similar tests
- Results from larger study not expected until Q1 2027, creating extended period of binary uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-237882 |
| Document: vrax-ex99_1.htm | 0001193125-26-237882 |
| Document: 0001193125-26-237882-index-headers.html | 0001193125-26-237882 |
| Document: 0001193125-26-237882.txt | 0001193125-26-237882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.17 (−36.76%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.17 (+55.51%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.17 (−55.43%) |
Aug 18, 2026 10w ago | 6-K | $2.76 | awaiting T+60 | — | $1.17 (−57.61%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.17 (+55.34%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.17 (−70.00%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.17 (+81.60%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.17 (−81.60%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.17 (+766.67%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.17 (+535.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers